This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EARL D. OSBORNE, M.D.; JAMES W. JORDON, M.D.; NORBERT G. RAUSCH, M.D.

Arch Derm Syphilol. 1947;55(3):309-321.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN 1927 Lewis¹ postulated that allergic reactions depend on or are produced by the liberation of a histamine-like substance (H substance) at the site of the reaction. Most investigators are of the opinion that histamine and the H substance are identical or nearly so. Many investigators have sought ways and means of neutralizing this H substance and thus preventing the sequence of events that occurs in allergic reactions. In 1932 Hill and Martin² reviewed the literature on antihistaminic substances and methods of preventing anaphylactic shock that had been described up to that time. None of these methods were effective. Since then, however, rapid progress has been made along this line.

Fourneau and Bovet, in 1933,³ pointed out that the drug thymoxyethyldiethylamine (929 F) had the ability to counteract the effects of histamine both in vitro and in vivo. Subsequently, this phenolic ether and others were studied for . . . [Full Text PDF of this Article]

Author Affiliations
BUFFALO

Footnotes
Read at the Sixty-Sixth Annual Meeting of the American Dermatological Association, Hot Springs, Va., June 10, 1946.

The pyribenzamine used in this study was furnished through the courtesy of Ciba Pharmaceutical Products, Inc., of Summit, N. J.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?